Moxifloxacina Krka

Moxifloxacin, the active ingredient in Moxifloxacina Krka, is a fluoroquinolone presented as an oral tablet for oral use. It treats a range of bacterial infections, including community‑acquired pneumonia, sinusitis, bronchitis, skin infections and intra‑abdominal infections in adult patients.

GNH USA supplies Moxifloxacina Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacina Krka is a fluoroquinolone antibacterial indicated for several bacterial infections.

- Community‑acquired bacterial pneumonia: achieves clinical cure and bacterial eradication. - Acute bacterial sinusitis: reduces symptoms and eliminates the causative pathogens. - Acute bacterial exacerbation of chronic bronchitis: improves airflow and resolves infection. - Skin and skin structure infections: clears bacterial involvement and promotes healing. - Intra‑abdominal infections: provides effective bacterial clearance in complicated cases.

Moxifloxacina Krka may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness - Abdominal pain - Rash

Serious or Rare Side Effects: - Tendon rupture or tendinitis - QT interval prolongation leading to arrhythmia - Clostridioides difficile‑associated colitis - Severe allergic reactions (anaphylaxis, Stevens‑Johnson syndrome) - Hepatic dysfunction - Photosensitivity

Before prescribing Moxifloxacina Krka, clinicians should consider several safety measures.

- Assess renal function: adjust use in severe impairment. - Review cardiac history: avoid in patients with known QT prolongation. - Avoid concomitant use with other fluoroquinolones. - Monitor for tendon pain: discontinue if symptoms arise. - Use with caution in pregnancy: limited safety data available. - Store below 25°C: keep in the original pack, protect from moisture.

Moxifloxacina Krka can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concomitant use with systemic corticosteroids: increased risk of tendon rupture. - Co‑administration with QT‑prolonging drugs (e.g., quinidine, macrolides): heightened arrhythmia risk. - Combination with antacids containing aluminum or magnesium: markedly reduces moxifloxacin absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Theophylline: increased plasma levels; watch for toxicity. - Cyclosporine: elevated exposure; monitor renal function.